NUZ — Neurizon Therapeutics Share News
0.000.00%
Last trade - 00:00- AU$62.62m
- AU$53.22m
Brief: Neurizon Therapeutics' Ongoing Healey ALS Platform Trial Affirmed By FDA
Brief: Neurizon Therapeutics Says Dr Chris Bremer Commences As CEO
Brief: Neurizon Therapeutics Appoints Chris Bremer As Chief Executive Officer
Brief: Neurizon Therapeutics Enters Strategic Research And Development Financing Facility
Australia's Neurizon Therapeutics jumps on deal with US firm
Brief: Neurizon Therapeutics Executes Long-Term Supply Agreement With Elanco
Brief: Neurizon Therapeutics Receives Ethics Approval For Phase 1 Nuz-001 Oral Liquid Formulation Study
Brief: Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 Million
Brief: Neurizon Therapeutics Says Michael Thurn Resigns As Managing Director And CEO
Australia's Neurizon Therapeutics rises as HY loss narrows, revenue rises
Brief: Neurizon Therapeutics Posts Loss For Half Year Attributable Of A$5.5 Million
Brief: Neurizon Therapeutics Secures Registered Trademark Protection For Neurizon® Across All Priority Global Markets
Brief: Neurizon Therapeutics Says US FDA Denies Fast Track Designation For NUZ-001
Neurizon Therapeutics falls after US FDA denies fast track designation request
Brief: Neurizon Therapeutics Says Firm Commitments To Raise A$7.1 Million Via Placement
Australia's Neurizon Therapeutics drops to 2-year low on discounted placement
Brief: Neurizon Therapeutics Seeks Trading Halt
Australia's Neurizon Therapeutics jumps after US FDA clears ALS product for trial use
Brief: FDA Lifts Clinical Hold On Nuz-001